Improving treatment and prevention of cervical cancer in Kenya

  • Hampson, Ian (Corresponding participant)
  • Lynne Hampson (Participant)

Impact: Attitudes and behaviours, Awareness and understanding, Society and culture, Health and wellbeing

Narrative

Cervical cancer has a high mortality in low/middle income nations, where human papilloma virus (HPV) vaccines are unaffordable, there are no screening programs and limited surgical facilities. University of Manchester (UoM) preclinical research led to a clinical trial in Nairobi repurposing HIV protease inhibitors as a topical, self-applied treatment for HPV-related cervical dysplasia. This showed efficacy against HPV infection and all grades of dysplasia. All women followed up were disease-free one year later. Adoption of clinical practices from this trial, and recommendations from another study on survival of Kenyan women with advanced cervical cancer, has improved disease management in Nairobi by providing: specialist training for healthcare staff; free screening and treatment for ~3,000 women; reduced waiting times.
Impact date1 Aug 2013 → 31 Jul 2020
Category of impactAttitudes and behaviours, Awareness and understanding, Society and culture, Health and wellbeing
Impact levelBenefit

Research Beacons, Institutes and Platforms

  • Cancer
  • Manchester Cancer Research Centre

Documents & Links

Related content